<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04186208</url>
  </required_header>
  <id_info>
    <org_study_id>AAG-O-H-1633</org_study_id>
    <nct_id>NCT04186208</nct_id>
  </id_info>
  <brief_title>Non-interventional Study With NOVOCART® 3D for the Treatment of Cartilage Defects of the Knee in Pediatric Patients</brief_title>
  <acronym>JUNOVO</acronym>
  <official_title>Prospective, Non-interventional Study to Evaluate the Efficacy and Safety of NOVOCART® 3D for the Treatment of Cartilage Defects of the Knee in Pediatric Patients With Closed Epiphyses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tetec AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aesculap AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Winicker Norimed GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tetec AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multicenter, single-arm non-interventional study to evaluate the efficacy,&#xD;
      safety and health economics of NOVOCART 3D in the Treatment fo cartilage defects of the knee&#xD;
      in pediatric patients wieh closed epiphyseal growth plates.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present study is a prospective, multicenter, single-arm non-interventional study to&#xD;
      evaluate the efficacy, safety and health economics of NOVOCART® 3D in the treatment of&#xD;
      cartilage defects of the knee in pediatric patients with closed epiphyseal growth plates.&#xD;
&#xD;
      In this non-interventional study NOVOCART® 3D, which is marketed in Germany under Paragraph&#xD;
      4b Medicinal Products Act, will be used in routine clinical practice according to the&#xD;
      authorized Summary of Product Characteristics (SmPC). As stated in this SmPC, NOVOCART® 3D&#xD;
      may only be used by physicians who are trained on the product. The treatment with NOVOCART®&#xD;
      3D requires two surgeries. During the first surgery cartilage biopsies will be harvested&#xD;
      arthroscopically and sent to TETEC AG (Tissue Engineering Technologies AG) for NOVOCART® 3D&#xD;
      manufacturing, then NOVOCART® 3D will be transplanted during a second surgery about 3 to 4&#xD;
      weeks later.&#xD;
&#xD;
      All patients will be followed up for 5 years post NOVOCART® 3D transplantation and data will&#xD;
      be collected at 3, 6, 12, 18, 24, 36, 48 and 60 months as outlined at the end of this&#xD;
      synopsis.&#xD;
&#xD;
      NOVOCART® 3D post treatment rehabilitation should follow the recommendations given in the&#xD;
      SmPC and during product training.&#xD;
&#xD;
      The primary and secondary variables (see below) will be assessed after a follow-up of 24&#xD;
      month post NOVOCART® 3D transplantation (primary analysis).&#xD;
&#xD;
      Long-term data will be assessed after an additional 3 years follow-up (follow-up analysis).&#xD;
&#xD;
      The collected data will be documented using dedicated case report forms (CRFs) which are&#xD;
      created and printed by TETEC AG.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 25, 2017</start_date>
  <completion_date type="Anticipated">June 2026</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Overall KOOS (Knee Injury and Osteoarthritis Outcome Score)</measure>
    <time_frame>24 months Follow Up (FU)</time_frame>
    <description>Change of KOOS defined as the average of the 5 subscale scores (range 0-100, higher values represent a better outcome)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of 5 subscores KOOS</measure>
    <time_frame>24 months FU</time_frame>
    <description>Change of the 5 subscores of KOOS (range 0-100, higher values represent a better outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IKDC subjective</measure>
    <time_frame>24 month FU</time_frame>
    <description>Change of IKDC (International Knee Documentation Committee) subjective (range 0-100, higher values represent a better outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain VAS</measure>
    <time_frame>24 month FU</time_frame>
    <description>Change in pain VAS (Visual Analogue Scale) (range 0-10, higher values represent a better outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MOCART</measure>
    <time_frame>24 month FU</time_frame>
    <description>In vivo Performance via MRI (Magnetic Resonance Imaging), MOCART Score (Magnetic Resonance Observation of Cartilage Repair Tissue) (range 0-100, higher values represent a better outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KOOS responder rate</measure>
    <time_frame>24 month FU</time_frame>
    <description>KOOS responder rate defined as Proportion of patients with &gt; 10 Points improvement in KOOS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IKDC subjective responder rate</measure>
    <time_frame>24 months FU</time_frame>
    <description>IKDC subjective responder rate defined as Proportion of patients with &gt;20.5 Points improvement in IKDC subjective</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with Treatment failures</measure>
    <time_frame>3 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months</time_frame>
    <description>Proportion of patients with Treatment failures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economics variable (Days of missing work/school ) to NOVOCART 3D treatment</measure>
    <time_frame>3 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months</time_frame>
    <description>Days of missing work/school due to knee pain/function issues in the target knee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economics variable (Days of hospitalization ) to NOVOCART 3D treatment</measure>
    <time_frame>3 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months</time_frame>
    <description>Days of hospitalization due to knee pain/function issues in the target knee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economics variable (Number of postoperative doctor visits) to NOVOCART 3D treatment</measure>
    <time_frame>3 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months</time_frame>
    <description>Number of postoperative doctor visits</description>
  </secondary_outcome>
  <enrollment type="Actual">42</enrollment>
  <condition>Cartilage Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NOVOCART 3D</intervention_name>
    <description>Autologous Chondrocyte Implantation</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study will include pediatric patients (&lt; 18 years of age) with closed epiphyses who&#xD;
        suffer from a full-thickness cartilage defect of the knee caused by acute or repetitive&#xD;
        trauma or by osteochondritis dissecans and who are scheduled for treatment with NOVOCART®&#xD;
        3D. Further inclusion/exclusion criteria are given in the current version of the NOVOCART®&#xD;
        3D SmPC, where the therapeutic indications, contraindications, special warnings and&#xD;
        precautions for use are listed in detail.&#xD;
&#xD;
        The decision to treat patients with NOVOCART® 3D must be made independently from the&#xD;
        patient's participation in the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  13 - 17 years old&#xD;
&#xD;
          -  Medicinal indication for NOVOCART 3D treatment&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        • none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Angele, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Regensburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sportklinik Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden Württemberg</state>
        <zip>70372</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Theresienkrankenhaus und St. Hedwig-Klinik GmbH</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Württemberg</state>
        <zip>68165</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Orthophädie, Physikalische Medizin und Rehabilitation Knie- und Schulterorthopädie</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der technischen Universität München</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univerisätsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>93047</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lubinus Clinicum Kiel</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 7, 2019</study_first_submitted>
  <study_first_submitted_qc>December 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2019</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cartilage defect</keyword>
  <keyword>knee</keyword>
  <keyword>pediatric patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cartilage Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

